As the pharma giant already noted, it is getting rid of everything on the neurosciences side except its late-stage pain program allied with Eli Lilly. So the chopping block today includes a Phase I gamma secretes approach, PF-06648671, as well as a GABA-A receptor agonist for epilepsy and a dopamine 1 activator for cognitive disorders.
And that’s not all. There’s a Phase I myeloperoxidase inhibitor for NASH that didn’t make the cut and curiously an IDO1 inhibitor for cancer that will wrap up its presence in the pipeline.
The big setback for Pfizer was the failure of their PD-L1 checkpoint Bavencio for third line gastric cancer — which is being swept out into the scrap heap today.
That program isn’t going anywhere. But anyone interested in neurosciences should take a look at what Pfizer will likely hand over — cheap.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 25,000+ biopharma pros who read Endpoints News by email every day.Free Subscription